Slingshot members are tracking this corporate initiative:
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jun 30, 2016 Projected Implementation: Q2, 2016 Relevance Tracked Until: Q3, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Late-stage Cancer, Nivolumab, Opdivo, Metastatic Melanoma, Classical Hodgkin’s Lymphoma, Post-transplantation Brentuximab Vedotin, Pd-1 Immune Checkpoint Inhibitor, Nsclc, Enadenotucirev, Autologous Hematopoietic Stem Cell Transplant